Dr Eviana Alice Breuss is a CEO and Co-Founder of Tengena, USA, with more more than 30 years of experience in basic and translational research, previously served at Columbia University School of medicine, and NYU School of Medicine, as well as collaborated with Harvard University, Bristol-Myers Squibb, Cognate Therapeutics, Weill Cornell Presbyterian Medical Center, and Memorial Sloan Kettering Cancer Center, NY. She obtained her PhD in Biochemistry and Molecular Biology in 1998. Dr. Breuss has extensive experience in designing, developing, and implementing government, DoD, and non-profit organizations grants, clinical trials, and establishing lasting academia-industry partnerships. She has publications in peer-reviewed scientific journals, including Nature and American Journal of Pathology. Her recent interests are focused on implementation of integrated photonic architectures and metamaterial solutions for semiconductors and accelerated and quantum computing applications, based on Tengena's unique sub nanoscale advanced materials and plasmonic integration technologies. Her team has developed state-of-the-art fabrication platforms that merge precision inline plasma pulse systems and adaptive acoustics. This cutting-edge approach allows the assembly of advanced materials and metamaterials at pico- and nanoscale with unparalleled accuracy and consistency, ensuring superior material performance to unlock unprecedented control over electromagnetic, thermal, and optical properties at the sub nanoscale. This approach not only opens the new level for practical applications but opens the pathway for collaborative research in fundamentals of quantum physics, including the fascinating field of discrete time crystals, time symmetry, repulsive gravity, and quantum entanglement.